GlassScriptPhysician profile
Brooke Ellen Beckwith
NPI 1598288615
$12,677.19
in general payments reported to CMS, 2019-2025
47 companies · $2,587 in 2025
The $2,587 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $907 · 2022: $2,324 · 2023: $2,200 · 2024: $4,659 · 2025: $2,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,331 · Consulting Fee: $1,860 · Honoraria: $1,050 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $700 · Long Term Medical Supply Or Device Loan: $482 · Education: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,331.48 |
| Consulting Fee | $1,860.00 |
| Honoraria | $1,050.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $700.00 |
| Long Term Medical Supply Or Device Loan | $482.13 |
| Education | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,668.61 | 2021-2025 | Imfinzi, Enhertu, Lynparza |
| Incyte Corporation | $1,497.73 | 2021-2025 | Jakafi |
| G1 Therapeutics, INC. | $1,444.92 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $1,158.09 | 2024 | |
| Novartis Pharmaceuticals Corporation | $866.97 | 2022-2025 | |
| Cti Biopharma Corp. | $700.00 | 2023 | Vonjo |
| Gilead Sciences, INC. | $541.25 | 2022-2025 | Trodelvy |
| Nuvation Bio INC. | $540.00 | 2025 | Ibtrozi |
| Daiichi Sankyo INC. | $406.44 | 2021-2025 | Enhertu, Vanflyta, Injectafer |
| Janssen Biotech, INC. | $399.83 | 2023-2025 | Tecvayli, Darzalex, Carvykti |
| Genzyme Corporation | $299.65 | 2021-2025 | |
| Sobi, INC | $251.45 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $244.26 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $231.01 | 2022-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $225.14 | 2021-2025 | Ojjaara |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $202.76 | 2021-2025 | Opdivo |
| Pharmaessentia USA Corporation | $202.30 | 2023-2025 | Besremi |
| Eisai INC. | $185.04 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $182.00 | 2023-2025 | Vonvendi, Vpriv, Advate |
| Amgen INC. | $163.76 | 2022-2023 | Lumakras, Kyprolis |
| Lilly USA, LLC | $140.99 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Emd Serono, INC. | $132.71 | 2022-2025 | Bavencio |
| Seagen INC. | $120.78 | 2021 | |
| Genentech USA, INC. | $114.24 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $110.70 | 2022-2024 | Libtayo |
| Geron Corporation | $70.14 | 2025 | Rytelo |
| Pharmacyclics LLC, An Abbvie Company | $61.64 | 2022 | |
| Adaptive Biotechnologies Corporation | $58.04 | 2023-2024 | Clonoseq |
| Blueprint Medicines Corporation | $51.95 | 2022-2025 | Ayvakit |
| Novocure INC. | $40.86 | 2021-2022 | |
| Astellas Pharma US INC | $34.27 | 2025 | Vyloy |
| Array Biopharma INC | $34.26 | 2025 | Braftovi, Tukysa, Mektovi |
| Epizyme, INC. | $28.53 | 2022 | |
| Immunocore Limited | $27.95 | 2025 | Kimmtrak |
| Morphosys, US INC. | $22.25 | 2023 | Monjuvi |
| Adc Therapeutics America, INC. | $21.45 | 2025 | |
| Myriad Genetic Laboratories, INC. | $20.97 | 2025 | Precisetumor |
| Caris Mpi, INC. | $19.79 | 2025 | Mi Cancer Seek |
| Exelixis INC. | $19.75 | 2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $19.36 | 2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $18.70 | 2024 | |
| Pfizer INC. | $17.98 | 2025 | |
| Stemline Therapeutics INC. | $17.12 | 2023 | Orserdu |
| Aveo Pharmaceuticals, INC. | $16.72 | 2022 | |
| Legend Biotech USA INC. | $15.90 | 2025 | Carvykti |
| Rigel Pharmaceuticals, INC. | $15.73 | 2021 | |
| Taiho Oncology, INC. | $13.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Beckwith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.